Mesothelioma

New Immuno-Radiology Treatment Being Tested on Mesothelioma

Mesothelioma is a cancer with a bad prognosis that is primarily caused by asbestos exposure. There is no cure for mesothelioma, so people diagnosed with the disease do not have a great chance of living long past their diagnoses. Clinical trials are people’s best chance of finding a better treatment[…]

Read More »

Opdivo and Yervoy Combination Could Lengthen Aggressive Mesothelioma Sufferers’ Lives

The combination of Yervoy and Opdivo was tested on mesothelioma and the overall survival was promising.   The overall survival was 18.1 months versus 14.1 months for patients receiving just chemotherapy. This is the first time that a phase III trial had an improved survival with an immunotherapy combination in a[…]

Read More »

αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors

Primary Outcome Measures Dose-limiting toxicity (DLT) [ Time Frame: After 28 days of single infusion ] Safety Secondary Outcome Measures Maximum tolerated dose (MTD) [ Time Frame: After 28 days of single infusion ] Tolerability Objective response rate (ORR) [ Time Frame: Month 12 ] Clinical response will be assessed by RECIST 1.1. Progression-free survival (PFS) [ Time Frame: Month 12 ] PFS of patients receiving[…]

Read More »

Genetically Modified T-Cells for the Treatment of Mesothelioma and Other Tumors

Genetically modified T cells are a promising treatment for those suffering from mesothelioma. There is only data from five patients, but the results so far look good. The Phase I part of the study is looking at the safety and efficacy of the treatment and is finding out what dosage[…]

Read More »

Intravenous Magnesium in Patients Receiving Cisplatin

Primary Outcome Measures Feasibility and acceptability as measured by participant rates of enrollment [ Time Frame: 6 months ] Feasibility assessed by % of patients that agree to participate. Project feasible if >30% of the patients approached agree to participate Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE Version 5.0 [ Time Frame: Time[…]

Read More »

More Peritoneal Mesothelioma Patients Should be Receiving Surgery

Peritoneal mesothelioma is a rare condition with only 400 cases diagnosed every year. Patients diagnosed with the cancer are not living as long as they could because of the underutilization of surgery. Surgery is only performed on a third of patients even though there are people that would benefit and[…]

Read More »

High Resolution Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome

Primary Outcome Measures Prospectively gather information related to the use of high-resolution computed tomographic imaging (HRCT) including photon counting CT (PCCT) scans, together with minimally invasive surveillance for early detection of mesotheliomas in pts with … [ Time Frame: annual or bi-annual followup, 5 years interim analysis ] Documentation of[…]

Read More »

Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Malignant MESOthelioma (TALAMESO)

Primary Outcome Measures Non-progression proportion [ Time Frame: 6 month after starting talazoparib ] The non-progression proportion is defined as the proportion of patients free of            progression 6 months after talazoparib start. Disease progression will be based on (i) tumor assessment made by the investigators according to the RECIST[…]

Read More »

Halofuginone Could Soon be Used to Treat Mesothelioma

Mesothelioma is a devastating cancer that primarily affects the lining of the lungs and abdomen. Once exposed to asbestos, it can take years to develop and after being diagnosed, there are not many options for patients. Since there is not a cure, clinical trials can give people hope and can[…]

Read More »